NVCT
Income statement / Annual
Last year (2023), Nuvectis Pharma, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Nuvectis Pharma, Inc.'s net income was -$22.26 M.
See Nuvectis Pharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00
|
$149,000.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$22.90 M |
$19.23 M |
$12.89 M |
$0.00 |
| Gross Profit |
-$22.90 M |
-$19.09 M |
-$12.89 M |
$0.00 |
| Gross Profit Ratio |
0 |
-128.09 |
0 |
0 |
| Research and Development
Expenses |
$15.38 M
|
$13.23 M
|
$9.55 M
|
$0.00
|
| General & Administrative
Expenses |
$7.50 M
|
$6.01 M
|
$3.35 M
|
$24,000.00
|
| Selling & Marketing
Expenses |
$14,000.00
|
$0.00
|
$0.00
|
$9,976.00
|
| Selling, General &
Administrative Expenses |
$7.52 M
|
$6.01 M
|
$3.35 M
|
$10,000.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$22.90 M |
$19.23 M |
$12.89 M |
$10,000.00 |
| Cost And Expenses |
$22.90 M |
$19.23 M |
$12.89 M |
$10,000.00 |
| Interest Income |
$637,000.00 |
$149,000.00 |
$4,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
$149,000.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
-$1.00 M
|
-$1.20 M
|
-$7.10 M
|
$24,000.00
|
| EBITDA |
-$22.90 M
|
-$19.23 M
|
-$12.89 M
|
-$10,000.00
|
| EBITDA Ratio |
0 |
-129.09 |
0 |
0 |
| Operating Income Ratio
|
0
|
-129.09
|
0
|
0
|
| Total Other
Income/Expenses Net |
$637,000.00
|
$149,000.00
|
$4,000.00
|
$0.00
|
| Income Before Tax |
-$22.26 M |
-$19.09 M |
-$12.89 M |
-$10,000.00 |
| Income Before Tax Ratio
|
0
|
-128.09
|
0
|
0
|
| Income Tax Expense |
$1,000.00 |
-$298,000.00 |
-$4,000.00 |
-$24.00 |
| Net Income |
-$22.26 M |
-$18.79 M |
-$12.89 M |
-$10,000.00 |
| Net Income Ratio |
0 |
-126.09 |
0 |
0 |
| EPS |
-1.43 |
-1.48 |
-1.01 |
-0.0008 |
| EPS Diluted |
-1.43 |
-1.48 |
-1.01 |
-0.0008 |
| Weighted Average Shares
Out |
$15.56 M
|
$12.66 M
|
$12.72 M
|
$12.72 M
|
| Weighted Average Shares
Out Diluted |
$15.56 M
|
$12.66 M
|
$12.72 M
|
$12.72 M
|
| Link |
|
|
|
|
